BioCentury
ARTICLE | Company News

Takeda ends Japan deal for two Amgen candidates

June 25, 2016 12:22 AM UTC

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it returned its Japanese rights to fulranumab ( AMG 403) and trebananib ( AMG 386) to Amgen Inc. (NASDAQ:AMGN).

In April, Johnson & Johnson (NYSE:JNJ) said it discontinued Phase III development of fulranumab to treat osteoarthritis pain, and returned the candidate's rights to Amgen. J&J had held exclusive ex-Japan rights to the IgG2 mAb against nerve growth factor (NGF) (see BioCentury Extra, April 1). ...